实用肝脏病杂志 ›› 2025, Vol. 28 ›› Issue (3): 386-389.doi: 10.3969/j.issn.1672-5069.2025.03.017

• 药物性肝损伤 • 上一篇    下一篇

药物性肝损伤患者血清miR-122、IL-1β和IL-10水平变化及其临床意义探讨*

熊钻, 程丰, 刘庆, 王亚, 沈利华   

  1. 436000 湖北省鄂州市鄂钢医院检验科(熊钻,刘庆,王亚);湖北科技学院附属鄂州市中心医院检验科(程丰,沈利华)
  • 收稿日期:2024-08-03 发布日期:2025-05-14
  • 通讯作者: 沈利华,E-mail:4458629@qq.com
  • 作者简介:熊钻,男,40岁,大学本科,副主任技师。E-mail:15871522689@163.com
  • 基金资助:
    *湖北省科学技术厅科研计划项目(编号:2022BCE064)

Serum miR-122, IL-1β and IL-10 level Changes in patients with drug-induced liver injury

Xiong Zuan, Cheng Feng, Liu Qing, et al   

  1. Clinical Laboratory, Egang Hospital, Ezhou 436000, Hubei Province, China
  • Received:2024-08-03 Published:2025-05-14

摘要: 目的 探讨药物性肝损伤(DILI)患者血清微小RNA-122(miR-122)、白介素-1β(IL-1β)和IL-10水平变化及其临床意义。方法 2023年1月~2024年6月我院收治的DILI患者139例(胆汁淤积型39例,肝细胞损伤型86例,混合型14例;肝损伤1级43例,2级60例,3级36例)和同期体检的健康人75例,采用逆转录实时荧光定量PCR法检测血清miR-122水平,采用ELISA法检测血清IL-1β和IL-10水平。结果 DILI组血清总胆红素、ALT、AST、ALP和GGT水平为(48.6±7.9)μmol/L、(117.9±35.8)U/L、(112.8±42.3)U/L、(193.2±46.5)U/L和(377.6±88.8)U/L,均显著高于健康人组【分别为(10.3±3.2)μmol/L、(24.8±5.4)U/L、(23.1±4.0)U/L、(49.7±17.8)U/L和(50.4±4.2)U/L,P<0.05】;混合型血清miR-122水平为(11.5±2.6),肝细胞损伤型为(10.9±1.6),均显著高于胆汁淤积型【(9.0±1.5),P<0.05】,混合型血清IL-1β水平为(105.3±3.8)pg/mL,肝细胞损伤型为(101.8±3.2)pg/mL,均显著高于胆汁淤积型【(90.6±13.0)pg/mL,P<0.05】,三组血清IL-10水平无显著性差异(P>0.05);3级DILI患者血清miR-122水平为(12.5±1.2),2级DILI患者为(10.3±1.4),均显著高于1级患者【((8.6±1.5),P<0.05】,3级DILI患者血清IL-1β水平为(105.1±13.2)pg/mL,2级为 (100.7±13.4)pg/mL,均显著高于1级【(88.8±13.1)pg/mL,P<0.05】,3级DILI患者血清IL-10水平为(1.9±0.8)pg/mL,2级为(2.1±0.9)pg/mL,均显著低于1级DILI患者【(2.8±1.1)pg/mL,P<0.05】。结论 DILI患者血清miR-122和IL-1β水平升高,而血清IL-10水平降低,可能与病情严重程度有关,值得进一步研究。

关键词: 药物性肝损伤, 微小RNA-122, 白介素-1β, 白介素-10, 临床意义

Abstract: Objective The aim of this study was to explore clinical implication of serum microRNA-122 (miR-122), interleukin-1beta (IL-1β) and IL-10 levels in patients with drug-induced liver injury (DILI). Methods 139 patients with DILI and 75 individuals for physical examination were admitted to our hospital between January 2023 and June 2024, and thecatalogue of patients with DILI included cholestatic type in 39 cases, hepatocyteinjury type in 86 cases and mixed type in 14cases, and grade 1 in 43 cases, grade 2 in 60 cases and grade 3 in 36 cases based on liver injury severity. Serum miR-122 level was detected by real-time reverse transcription polymerase chain reaction (RT-PCR), and serum IL-1β and IL-10 levels were assayed by ELISA. Results Serum bilirubin, alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase and gamma-glutamyl transferase levels in patients with DILI were(48.6±7.9)μmol/L, (117.9±35.8)U/L,(112.8±42.3)U/L, (193.2±46.5)U/L and (377.6±88.8)U/L, all significantly higher than [(10.3±3.2)μmol/L, (24.8±5.4)U/L, (23.1±4.0)U/L, (49.7±17.8)U/L and (50.4±4.2)U/L, respectively, P<0.05] in the control; serum miR-122 level in patients with mixed type was(11.5±2.6)and in those with hepatocyteinjury typewas(10.9±1.6), both much higher than [(9.0±1.5),P<0.05] in those with cholestatic type, serum IL-1β level in patients with mixed type was (105.3±3.8)pg/mL and in those with hepatocyte injury type was (101.8±3.2)pg/mL, both much higher than [(90.6±13.0)pg/mL, P<0.05] in those with cholestatic type, while there were no significant differences as respect to serum IL-10 levels among the three groups (P>0.05); serum miR-122 level in patients with grade 3 was (12.5±1.2), and in those with grade 2was (10.3±1.4), both much higher than [((8.6±1.5),P<0.05] in patients with grade 1 liver injury, serum IL-1β level in patients with grade 3 was (105.1±13.2)pg/mL, and in those with grade 2 was (100.7±13.4)pg/mL, both significantly higher than [(88.8±13.1)pg/mL, P<0.05] in those with grade 1, while serum IL-10 level in patients with grade 3 was (1.9±0.8)pg/mL, and in those with grade 2 was (2.1±0.9)pg/mL, both significantly lower than [(2.8±1.1)pg/mL, P<0.05]in those with grade 1 liver injury. Conclusion Serum miR-122,IL-1β and IL-10 level changes in patients with DILI might hint severity of liver injuries, and warrant further clinical investigation.

Key words: Drug-induced liver injury, MicroRNA-122, Interleukin-1β, Interleukin-10, Implications